Cardiac troponin and COVID-19 severity: Results from BIOCOVID study

Citations of this article
Mendeley users who have this article in their library.

This artice is free to access.


Background: Myocardial injury is a common finding in COVID-19 strongly associated with severity. We analysed the prevalence and prognostic utility of myocardial injury, characterized by elevated cardiac troponin, in a large population of COVID-19 patients, and further evaluated separately the role of troponin T and I. Methods: This is a multicentre, retrospective observational study enrolling patients with laboratory-confirmed COVID-19 who were hospitalized in 32 Spanish hospitals. Elevated troponin levels were defined as values above the sex-specific 99th percentile upper reference limit, as recommended by international guidelines. Thirty-day mortality was defined as endpoint. Results: A total of 1280 COVID-19 patients were included in this study, of whom 187 (14.6%) died during the hospitalization. Using a nonspecific sex cut-off, elevated troponin levels were found in 344 patients (26.9%), increasing to 384 (30.0%) when a sex-specific cut-off was used. This prevalence was significantly higher (42.9% vs 21.9%; P




García de Guadiana-Romualdo, L., Morell-García, D., Rodríguez-Fraga, O., Morales-Indiano, C., María Lourdes Padilla Jiménez, A., Gutiérrez Revilla, J. I., … Consuegra-Sánchez, L. (2021). Cardiac troponin and COVID-19 severity: Results from BIOCOVID study. European Journal of Clinical Investigation, 51(6).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free